LIFE Stock Recent News

NEW ORLEANS , May 17, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period"). Long term holders of GL are also encouraged to contact the firm.

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units (each, a “Unit”), at a price of $0.04 per Unit; (the “Offering”). The Offering is being led by EMD Financial Inc.

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. “These findings further demonstrate the unique way in which efzofitimod is modulating myeloid cells to confer the anti-inflammatory benefits we have seen in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD),” said Sanjay S.

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024. Details of the conferences appear below: Conference: Evercore ISI Diamonds in the Rough Webinar DayDate: Thursday, April 4, 2024 Time: 10:30am EDTLocation: VirtualFormat: Corporate Presentation with Q&A Session Conference: Piper Sandler Spring Biopharma SymposiumDate: Wednesday, April 17, 2024Location: Everett, MAFormat: 1x1 Investor Meetings For more information on how to register, please contact your Evercore ISI or Piper Sandler representative.

When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?

aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2023 financial results and provide a corporate update after the market close on Thursday, March 14, 2024. Management will host a conference call and webcast to review the results and provide an operational update.

Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of companies that make life in the financial markets, we can always identify good investment opportunities that allow us to add value to our portfolio and our wealth.

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D.

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap American Woodmark (AMWD), Skechers (SKX), Workday (WDAY), aTyr Pharma (LIFE) and Modine Manufacturing (MOD).